Champions Oncology, Inc. (CSBR)
NASDAQ: CSBR · Real-Time Price · USD
7.40
-0.50 (-6.33%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Champions Oncology Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Champions Oncology stock has a target of 12, which predicts an increase of 62.16% from the current stock price of 7.40.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 12, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Champions Oncology is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $8 → $12 | Strong Buy | Maintains | $8 → $12 | +62.16% | Mar 12, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $6 → $8 | Strong Buy | Maintains | $6 → $8 | +8.11% | Dec 12, 2024 |
| Craig-Hallum | Craig-Hallum | Hold → Strong Buy Upgrades $6 | Hold → Strong Buy | Upgrades | $6 | -18.92% | Sep 12, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 13, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $9 → $7.5 | Strong Buy | Maintains | $9 → $7.5 | +1.35% | Sep 22, 2023 |
Financial Forecast
Revenue This Year
57.73M
from 50.16M
Increased by 15.11%
Revenue Next Year
62.24M
from 57.73M
Increased by 7.80%
EPS This Year
0.31
from -0.54
EPS Next Year
0.22
from 0.31
Decreased by -26.67%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 59.4M | 64.1M | 84.0M | |||
| Avg | 57.7M | 62.2M | 81.6M | |||
| Low | 55.5M | 59.8M | 78.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 18.5% | 11.0% | 35.0% | |||
| Avg | 15.1% | 7.8% | 31.2% | |||
| Low | 10.6% | 3.6% | 26.0% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | 0.32 | 0.23 |
| Avg | 0.31 | 0.22 |
| Low | 0.29 | 0.22 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | -24.5% |
| Avg | - | -26.7% |
| Low | - | -29.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.